Ramon Roozendaal
Overview
Explore the profile of Ramon Roozendaal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swart M, Kuipers H, Milder F, Jongeneelen M, Ritschel T, Tolboom J, et al.
NPJ Vaccines
. 2023 Nov;
8(1):176.
PMID: 37952003
Seasonal influenza vaccines must be updated annually and suboptimally protect against strains mismatched to the selected vaccine strains. We previously developed a subunit vaccine antigen consisting of a stabilized trimeric...
2.
McLean C, Dijkman K, Gaddah A, Keshinro B, Katwere M, Douoguih M, et al.
Front Immunol
. 2023 Sep;
14:1215302.
PMID: 37727795
Introduction: In the absence of clinical efficacy data, vaccine protective effect can be extrapolated from animals to humans, using an immunological biomarker in humans that correlates with protection in animals,...
3.
Van Coillie J, Pongracz T, Sustic T, Wang W, Nouta J, Le Gars M, et al.
iScience
. 2023 Sep;
26(9):107619.
PMID: 37670790
IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved -linked glycan located in the IgG...
4.
Dari A, Solforosi L, Roozendaal R, Hoetelmans R, Perez-Ruixo J, Boulton M
J Pharmacol Exp Ther
. 2023 Aug;
387(1):121-130.
PMID: 37536955
Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biologic drivers in antibody production. We used a six-compartment mechanistic model to...
5.
Swart M, Lubbe J, Schmit-Tillemans S, van Huizen E, Verspuij J, Izquierdo Gil A, et al.
NPJ Vaccines
. 2023 Mar;
8(1):40.
PMID: 36927774
Since the original outbreak of the SARS-CoV-2 virus, several rapidly spreading SARS-CoV-2 variants of concern (VOC) have emerged. Here, we show that a single dose of Ad26.COV2.S (based on the...
6.
Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop J, et al.
NPJ Vaccines
. 2022 Nov;
7(1):156.
PMID: 36450746
Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for...
7.
Finch C, Dowling W, King T, Martinez C, Nguyen B, Roozendaal R, et al.
Vaccines (Basel)
. 2022 Sep;
10(9).
PMID: 36146462
The FDA Animal Rule was devised to facilitate approval of candidate vaccines and therapeutics using animal survival data when human efficacy studies are not practical or ethical. This regulatory pathway...
8.
Tiemessen M, Solforosi L, Dekking L, Czapska-Casey D, Serroyen J, Sullivan N, et al.
Vaccines (Basel)
. 2022 Aug;
10(8).
PMID: 36016151
The Marburg virus (MARV) and Sudan virus (SUDV) belong to the filovirus family. The sporadic human outbreaks occur mostly in Africa and are characterized by an aggressive disease course with...
9.
Roozendaal R, Solforosi L, Stieh D, Serroyen J, Straetemans R, Dari A, et al.
Nat Commun
. 2021 Oct;
12(1):5877.
PMID: 34620860
Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural...
10.
Solforosi L, Kuipers H, Jongeneelen M, Huber S, van der Lubbe J, Dekking L, et al.
J Exp Med
. 2021 Apr;
218(7).
PMID: 33909009
Safe and effective coronavirus disease-19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and...